鑽石生技投資股份有限公司

鑽石生技投資 (股票代號：6901) 是台灣第一家大型永續型生技創投，創始股東包含中天生技、富邦金控、台新金控及潤泰集團，秉持「扶植創新、關懷生命」的使命，迄今於海內外投資及育成20多家優秀生技新創公司。 鑽石專注生技醫療投資領域，鎖定全球具國際競爭力投資標的，包括新藥研發、高階醫療器材、創新醫療服務科技、醫療通路、農業生技等。鑽石最大的價值在於提供被投資企業在公司治理、技術研發、臨床執行、商業發展、資本市場接軌等不同面向的協助，加速被投資企業實現價值。 鑽石以成為具國際影響力的生技創投為願景，未來持續追求： -全球佈局投資 -轉化前瞻科技，成為滿足醫療缺口之產品 -育成具國際競爭力的生技醫療企業 -創造穩定投資價值與報酬率 -聲譽卓越、值得信賴的創投品牌 Diamond Biofund is an evergreen biotech venture capital headquartered in Taipei. The founding shareholders include Microbio Group, Fubon Financial, Taishin Holdings, and Ruentex Group, adhering to the mission of “Supporting Innovation” and “Caring for Life.” We have incubated and invested in more than 20 extraordinary entrepreneurs and companies domestically, regionally and globally, while many of them had successfully entered capital markets. The company specializes in biotechnology and medical investments, with focused areas in new drug research and development, high-end medical equipment, innovative medical service technology, medical channel, and agricultural biotechnology, etc. Diamond Biofund seeks to provide portfolio companies with our insights, network, as well as global resources. We recruit talents from diversified cultures and professions including corporate governance, technology R&D, clinical implementation, business development, capital market, and other disciplines. We strive to accelerate the success of our portfolio companies. With the vision of becoming a world class biotech venture capital, Diamond Biofund continue to: ・Access global investment opportunities ・Translate state-of-the-art technologies into innovative products that fill in gaps in medical needs ・Build world-class competitive biotech and medical enterprises ・Create significant investment values and deliver stable returns ・Become a reputable, trustworthy, and recognized venture capital 績效回顧 (2013-2023) -原始股東10年投報率達17倍 -創造2家市值超過300億元生技新藥企業 -支持6所頂尖大學及研究機構(中研院、台大、清大、北醫、國防、中興)，衍生7家生技新創企業，其中4家已進入資本市場或被併購 -支持高端人才培育與醫學研究超過新台幣6億元 -台灣第一家創投公司獲准掛牌上市